Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sk Biopharmaceuticals Co. Ltd.
Industry Sector: HealthTechnology
CEO: Dong-Hoon Lee
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 36.78
Exchange/Ticker 1: KRX:326030
Exchange/Ticker 2: N/A
Latest Market Cap: $5,736,686,282
BioCentury | Jul 22, 2024
Deals
Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal
Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia
BioCentury | Oct 9, 2023
Deals
Mirati takeout offers BMS upside beyond KRAS drug
Deal for $4.8B up front includes $1B contingent value right associated with milestone for PRMT5 program
BioCentury | Apr 15, 2023
Discovery & Translation
PRMT5 heats up at AACR23
The enzyme target represents a synthetic lethal precision medicine opportunity for 15% of all human cancers
BioCentury | Dec 1, 2022
Management Tracks
Lee to take the helm at SK Biopharmaceuticals
Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
BioCentury | Apr 30, 2022
Regulation
Panel set for trio of COVID vaccines
Plus EMA reviewing GSK, Sanofi’s Vidprevtyn and updates from Novartis and more
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Dec 16, 2021
Data Byte
Korean biopharma leads top IPOs of 2021
Each of this year’s top 25 IPOs raised over $250M; it’s the second straight win for a Korean company
BioCentury | Aug 10, 2021
Deals
Seagen deal for differentiated ADC lifts RemeGen’s valuation to nearly $8B
Partners believe asset can address conditions for which other ADCs haven’t been approved
BioCentury | May 28, 2021
Product Development
CEPI’s backing is latest boost for SK bioscience’s COVID-19 vaccine hub
CEPI’s $173.4 million commitment to SK bioscience will push the company’s COVID-19 vaccine into pivotal testing and expand its development for variants. The injection is the latest
BioCentury | May 1, 2021
Deals
European translation sees more money but fewer start-ups in 2020
Academia remains the primary source of innovation, but industry spinouts rose in number last year
Items per page:
1 - 10 of 50